{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "exchange": "NMS", "shortName": "LAVA Therapeutics N.V.", "longName": "LAVA Therapeutics N.V.", "messageBoardId": "finmb_546792242", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "marketState": "REGULAR", "regularMarketChangePercent": -3.768419, "regularMarketPrice": 1.8284, "regularMarketChange": -0.07159996, "regularMarketTime": 1684262047, "firstTradeDateMilliseconds": 1616765400000, "priceHint": 4, "regularMarketDayHigh": 1.9, "regularMarketDayRange": "1.811 - 1.9", "regularMarketDayLow": 1.811, "regularMarketVolume": 10047, "regularMarketPreviousClose": 1.9, "bid": 1.82, "ask": 1.89, "bidSize": 8, "askSize": 8, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 1.865, "averageDailyVolume3Month": 64258, "averageDailyVolume10Day": 38490, "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyTwoWeekLowChange": 0.4634, "fiftyTwoWeekLowChangePercent": 0.3394872, "fiftyTwoWeekRange": "1.365 - 7.38", "fiftyTwoWeekHighChange": -5.5516, "fiftyTwoWeekHighChangePercent": -0.7522493, "fiftyTwoWeekLow": 1.365, "fiftyTwoWeekHigh": 7.38, "earningsTimestamp": 1681210800, "earningsTimestampStart": 1684240200, "earningsTimestampEnd": 1684499400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.24, "epsForward": -2.05, "epsCurrentYear": -2.1, "priceEpsCurrentYear": -0.87066674, "sharesOutstanding": 26289100, "bookValue": 3.273, "fiftyDayAverage": 1.6925, "fiftyDayAverageChange": 0.13590002, "fiftyDayAverageChangePercent": 0.080295436, "twoHundredDayAverage": 3.17477, "twoHundredDayAverageChange": -1.3463701, "twoHundredDayAverageChangePercent": -0.42408428, "marketCap": 48066992, "forwardPE": -0.89190245, "priceToBook": 0.55863124, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-03-25", "averageAnalystRating": "1.4 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "displayName": "LAVA Therapeutics", "symbol": "LVTX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Yalelaan 60", "city": "Utrecht", "zip": "3584 CM", "country": "Netherlands", "phone": "31 630 00 30 35", "website": "https://www.lavatherapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 69, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen Allen Hurly M.B.A., M.Sc.", "age": 54, "title": "CEO, Pres & Exec. Director", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Fred M. Powell CPA", "age": 61, "title": "Chief Financial Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Hans  van der Vliet M.D., Ph.D.", "age": 48, "title": "Chief Scientific Officer", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Amy  Garabedian J.D.", "age": 46, "title": "Gen. Counsel & Corp. Sec.", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Wouter van Hunnik", "title": "VP & Head of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ton  Adang Ph.D.", "age": 61, "title": "Chief Devel. Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Paul W. H. I. Parren Ph.D.", "age": 58, "title": "Exec. VP & MD", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}